Apoptosis and the liver

Seminars in Cancer Biology

Volumn 10, Issue 3, 2000, Pages 173-184

  Kanzler, Stephan ^a   Galle, Peter Robert ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Apoptosis; Fas; Liver; TGF beta; TNF alpha

Indexed keywords

ACTIVIN A; CERAMIDE; DNA; FAS LIGAND; LIGAND; MYC PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; DNA DAMAGE; HUMAN; LIGAND BINDING; LIVER; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FAILURE; LIVER INJURY; LIVER TRANSPLANTATION; MALIGNANT TRANSFORMATION; NONHUMAN; RAT; REVIEW; VIRUS HEPATITIS;

EID: 0033852975     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.2000.0318     Document Type: Article

References (189)

1. Social controls on cell survival and cell death
2. Apoptosis, oncosis, and necrosis. An overview of cell death
3. Shrinkage necrosis: A distinct mode of cellular death
4. Apoptosis
5. Liver cell necrosis: Cellular mechanisms and clinical implications
6. Apoptosis and hepatobiliary disease
7. Cell death (apoptosis) in cell culture systems
8. Apoptosis in liver disease
9. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis
10. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen
11. Mechanisms and genes of cellular suicide
12. The Fas death factor
13. Apoptosis in the pathogenesis and treatment of disease
14. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95
15. CAR1, a TNFR-related protein, is a cellular receptor for cytopathic avian leukosis-sarcoma viruses and mediates apoptosis
16. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family
17. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage
18. Lethal effect of the anti-Fas antibody in mice
19. Anti-Fas on nonhematopoietic tumors: Levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness
20. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family
21. Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases
22. Fas ligand in human serum
23. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC)
24. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling
25. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis
26. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C
27. CD95-induced apoptosis in human liver disease
28. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity
29. Apoptosis as a mechanism of cell death in liver allograft rejection
30. Ultrastructural lesions of bile ducts in primary biliary cirrhosis. A comparison with the lesions observed in graft versus host disease
31. Tumor necrosis factor, other cytokines and disease
32. Two tumor necrosis factor receptors: Structure and function
33. Modulation of life and death by the TNF receptor superfamily
34. Two TNF receptors
35. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death
36. Tumor necrosis factor's cytotoxic activity is signaled by the p55 TNF receptor
37. Death receptors in liver biology and pathobiology
38. Glutathione modulates rat and mouse hepatocyte sensitivity to tumor necrosis factor toxicity
39. Murine hepatocyte apoptosis induced in vitro and in vivo by TNF-alpha requires transcriptional arrest
40. NF-kappaB inactivation converts a hepatocyte cell line TNF-alpha response from proliferation to apoptosis
41. Activation of the 55 kDa TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, and nitrite release
42. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection
43. Increased plasma tumor necrosis factor in severe alcoholic hepatitis
44. Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat
45. Enhanced tumor necrosis factor and interleukin-1 in fulminant hepatic failure
46. Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis
47. Production and role of interleukin-10 in concanavalin A-induced hepatitis in mice
48. Suppression of concanavalin A-induced hepatitis in IFN-gamma (-/-) mice, but not in TNF-alpha(-/-) mice: Role for IFN-gamma in activating apoptosis of hepatocytes
49. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
50. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL
51. A novel receptor for Apo2L/TRAIL contains a truncated death domain
52. TRAIL causes cleavage of bid by caspase-8 and loss of mitochondrial membrane potential resulting in apoptosis in BJAB cells
53. Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta)
54. Control of transforming growth factor-beta activity: Latency vs. activation
55. Characterization of the activation of latent TGF-beta by cocultures of endothelial cells and pericytes or smooth muscle cells: A self-regulating system
56. Differential regulation of expression of three transforming growth factor beta species in human breast cancer cell lines by estradiol
57. TGF-beta receptors and actions
58. TGF-beta-receptor-mediated signaling
59. Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors
60. TGF-beta signalling from cell membrane to nucleus through SMAD proteins
61. Smads: Transcriptional activators of TGF-beta responses
62. Molecular cloning and characterisation of TIEG2 reveals a new subfamily of transforming growth factor-beta-inducible Sp1-like zinc finger-encoding genes involved in the regulation of cell growth
63. The transforming growth factorβ1-inducible transcription factor, TIEGI, mediates apoptosis through oxidative stress
64. Induction of p53 and Bax during TGF-beta 1 initiated apoptosis in rat liver epithelial cells
65. Transforming growth factor-beta1 in autoimmune hepatitis: Correlation of liver tissue expression and serum levels with disease activity
66. In vitro and in vivo association of transforming growth factor-beta1 with hepatic fibrosis
67. Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy
68. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions
69. Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like syndrome in PEPCK-TGF-beta1 transgenic mice
70. Effect of transforming growth factor beta on cell death of cultured rat hepatocytes
71. Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor beta 1
72. Activin induces cell death in hepatocytes in vivo and in vitro
73. Transforming growth factor beta and tumor necrosis factor alpha inhibit both apoptosis and proliferation of activated rate hepatic stellate cells
74. Functions of ceramide in coordinating cellular responses to stress
75. Sphingomyelinases in cell regulation
76. Ceramide signalling: Regulatory role in cell proliferation, differentiation and apoptosis in human epidermis
77. Sphingomyelin breakdown and cell fate
78. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis
79. III. Intracellular signalling in response to toxic liver injury
80. Differential regulation of sphingomyelinase and ceramidase activities by growth factors and cytokines. Implications for cellular proliferation and differentiation
81. Role for ceramide in cell cycle arrest
82. Induction of apoptosis and potentiation of ceramide-mediated cytotoxicity by sphingoid bases in human myeloid leukemia cells
83. Ceramide formation leads to caspase-3 activation during hypoxic PC12 cell death. Inhibitory effects of Bcl-2 on ceramide formation and caspase-3 activation
84. Regulation of ceramide production and apoptosis
85. Mitogen-activated protein kinase-mediated Fas apoptopic signaling pathway
86. Ceramide induces hepatocyte cell death through disruption of mitochondrial function in the rat
87. Ceramide induces caspase-independent apoptosis in rat hepatocytes sensitized by inhibition of RNA synthesis
88. Caspase-independent cell death induced by anti-CD2 or staurosporine in activated human peripheral T lymphocytes
89. Efficient nuclear targeting of granzyme B and the nuclear consequences of apoptosis induced by granzyme B and perforin are caspase-dependent, but cell death is caspase-independent
90. A possible role of nuclear ceramide and sphingosine in hepatocyte apoptosis in rat liver
91. Ceramide-mediated apoptosis of hepatocytes in vivo: A matter of the nucleus?
92. Nitric oxide in liver injury
93. Mechanisms of nitric oxide-dependent apoptosis: Involvement of mitochondrial mediators
94. Modulation of the mitochondrial permeability transition by nitric oxide
95. Nitric oxide induces apoptosis via triggering mitochondrial permeability transition
96. DNA strand breakage and activation of poly-ADP ribosyltransferase: A cytotoxic pathway triggered by peroxynitrite
97. DNA damage induced by peroxynitrite: Subsequent biological effects
98. Nitric oxide inhibits apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms
99. Nitric oxide protects cultured rat hepatocytes from tumor necrosis factor-alpha-induced apoptosis by inducing heat shock protein 70 expression
100. NF-κB and nitric oxide protect primary mouse hepatocytes from Fas-mediated apoptosis
101. Apoptosis and the cell cycle
102. Cell cycle and apoptosis: Common pathways to life and death
103. Signal transduction pathways in apoptosis
104. DNA strand breaks: The DNA template alterations that trigger p53-dependent DNA damage response pathways
105. Participation of p53 protein in the cellular response to DNA damage
106. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53
107. Wild-type p53 is a cell cycle checkpoint determinant following irradiation
108. Thymocyte apoptosis induced by p53-dependent and independent pathways
109. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents
110. p53 is required for radiation-induced apoptosis in mouse thymocytes
111. Apoptosis, cancer and the p53 tumor suppressor gene
112. Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways
113. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies
114. p53 tumor suppressor gene: From the basic research laboratory to the clinic - An abridged historical perspective
115. p53 overexpression is frequent in European hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation
116. Clinical implications of the p53 tumor-suppressor gene
117. Myc family oncogenes in the development of normal and neoplastic cells
118. New light on Myc and Myb. Part I. Myc
119. Proteins of the Myc network: Essential regulators of cell growth and differentiation
120. C-myc gene amplification during hepatocarcinogenesis by a cholinedevoid diet
121. Expression of c-Ki-ras, c-Ha-ras, and c-myc in specific cell types during hepatocarcinogenesis
122. Cellular distribution of c-myc transcripts during chemical hepatocarcinogenesis in rats
123. Oncogene-induced liver neoplasia in transgenic mice
124. Characterization of trans-immortalized hepatic cell lines established from transgenic mice
125. Reduced growth capacity of hepatocytes from c-myc and c-myc/TGF-alpha transgenic mice in primary culture
126. BCL-2 gene family and the regulation of programmed cell death
127. Analysis of the structure transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma
128. The proto-oncogene Bcl-2 and its role in regulating apoptosis
129. New members of the Bcl-2 family and their protein partners
130. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax
131. A peptide sequence from Bax that converts Bcl-2 into an activator of apoptosis
132. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death
133. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death
134. Cytochrome c: Can't live with it-can't live without it
135. Heterodimerization-independent functions of cell death regulatory proteins Bax and Bcl-2 in yeast and mammalian cells
136. Bid induces the oligomerization and insertion of bax into the outer mitochondrial membrane
137. Interaction of DNA-dependent protein kinase and ploy(ADP-ribose) polymerase with radiation-induced DNA strand breaks
138. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase
139. Different cleavage pattern for poly(ADP-ribose) polymerase during necrosis and apoptosis in HL-60 cells
140. Active cell death (apoptosis) in liver biology and disease
141. Apoptosis and hepatocarcinogenesis
142. Food restriction eliminates preneoplastic cells through apoptosis and antagonizes carcinogenesis in rat liver
143. Oxidative stress-mediated apoptosis of hepatocytes exposed to acute ethanol intoxication
144. Ethanol feeding of micropigs alters methionine metabolism and increases hepatocellular apoptosis and proliferation
145. Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes
146. Fas antigen expression in liver tissues of patients with chronic hepatitis B
147. Role of Fas ligand in apoptosis induced by hepatitis C virus infection
148. Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis
149. Class I-restricted cytotoxic T lymphocytes are directly cytopathic for their target cells in vivo
150. Essential roles of the Fas ligand in the development of hepatitis
151. Multiple pathways of Fas-induced apoptosis in primary culture of hepatocytes
152. Suppression of apoptotic cell death by hepatitis C virus core protection
153. Sensitization to Fas-mediated apoptosis by hepatitis C virus core protein
154. Serum levels and in situ expression of TNF-alpha and TNF-alpha binding proteins in inflammatory liver diseases
155. Expression of antigens related to apoptosis and cell proliferation in chronic nonsuppurative destructive cholangitis in primary biliary cirrhosis
156. Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis
157. Rates of apoptosis and proliferation vary with caloric intake and may influence incidence of spontaneous hepatoma in C57BL/6 x C3H F1 mice
158. Piclass glutathione-S-transferase-positive hepatocytes in aging B6C3F1 mice undergo apoptosis induced by dietary restriction
159. Aging accelerates but lifelong dietary restriction suppresses apoptosis-related Fas expression on hepatocytes
160. The effect of two periods of short-term fasting during the promotion stage of hepatocarcinogenesis in rats: The role of apoptosis and cell proliferation
161. Apoptosis in the liver and its role in hepatocarcinogenesis
162. Inhibition of apoptosis during 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated tumor promotion in rat liver
163. Controlled death (apoptosis) of normal and putative preneoplastic cells in rat liver following withdrawal of tumor promoters
164. Cell proliferation and apoptosis in normal liver and preneoplastic foci
165. Suppression of liver cell apoptosis in vitro by the non-genotoxic hepatocarcinogen and peroxisome proliferator nafenopin
166. Influence of liver tumor promoters on apoptosis in rat hepatocytes induced by 2-acetylaminofluorene, ultraviolet light, or transforming growth factor beta 1
167. Occurrence of cell death (apoptosis) during the involution of liver hyperplasia
168. Sequential alterations in growth control and cell dynamics of rat hepatocytes in early precancerous steps in hepatocarcinogenesis
169. Determination of the length of the histological stages of apoptosis in normal liver and in altered hepatic foci of rats
170. Melanoma cell expression of Fas (Apo-1/CD95) ligand: Implications for tumor immune escape
171. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium
172. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cell - A mechanism of immune evasion?
173. Alteration in growth regulation of hepatocytes in primary culture obtained from cirrhotic rat: Poor response to transforming growth factor-beta 1 and interferons
174. Tumor suppressor activity of the TGF-beta pathway in human cancers
175. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability
176. Development of resistance to the growth inhibitory effects of transforming growth factor beta 1 during the spontaneous transformation of rat liver epithelial cells
177. Transforming growth factor beta 1 promotes spontaneous transformation of cultured rat liver epithelial cells
178. Constitutive expression of mature transforming growth factor beta1 in the liver accelerates hepatocarcinogenesis in transgenic mice
179. Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers
180. Elevated levels of transforming growth factor beta messenger RNA and its polypeptide in human hepatocellular carcinoma
181. Plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma. Comparison with chronic liver disease
182. Role of ischemia in causing apoptosis, atrophy, and nodular hyperplasia in human liver
183. Role of tumour necrosis factor-alpha in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat
184. The protective effects of L-arginine after liver ischaemia/reperfusion injury in a pig model
185. Apoptosis of bile duct epithelial cells in hepatic allograft rejection
186. Apoptosis in the human liver during allograft rejection and end-stage liver disease
187. Apoptosis and the expression of Fas and Fas ligand (FasL) antigen in rejection and reinfection in liver allograft specimens
188. The apoptosis protector, bcl-2 protein, is downregulated in bile duct epithelial cells of human liver allografts